Synektik po podziale: co dalej z robotami chirurgicznymi i debiut Syn2bio? – Cezary Kozanecki

Synektik will split into two companies. Cezary Kozanecki, the company's CEO, discussed the process of spinning off its innovation business into the new entity, its impact on Synektik, the market outlook for the industry, and the diagnostic molecule project being implemented by Syn2bio. 👉 Facebook: / strefainwestorow Here we publish breaking news from the stock market and the latest analyses daily. 📸 Instagram: /strefa.inwestorow Take a look behind the scenes at our editorial office, learn interesting investment facts, and see what the world of finance looks like from the inside. 🐦 X (Twitter): https://x.com/strefainw Stay up to date with market news and commentary in real time. The Warsaw Stock Exchange (GPW) will soon be adding a new biotechnology company to its trading floor. Syn2bio, which will have the most advanced project of an innovative molecule in Phase 3 clinical trials, is planning its debut. Furthermore, the management board declares that it has fully secured financing for its further development. Cezary Kozanecki discussed the potential of the project being spun off from Synektik and its commercialization possibilities in the latest episode of the podcast. "We consider commercialization to mean registering the product and launching its sales," emphasizes Synektik's CEO. Synektik itself will also benefit from this division, Kozanecki points out. The company's financial resources will be allocated more to dividends than to financing the development of its innovation arm. We discuss Synektik's business plans, new products, and competition from Chinese surgical robots in the latest episode of the "Procent Składny" podcast. Interview schedule: 01:20 – Why is Synektik splitting into two companies? 02:50 – Who will manage the new company, Syn2bio? 04:00 – Where did the idea for the innovative activity and the Syn2 molecule come from? 06:00 – What remains in Synektik and what will be transferred to the new company? 08:00 – What does it mean in practice that the molecule developed by Syn2 is diagnostic? 10:30 – How does the cardiomarker stand out in the market? 13:00 – Clinical trials of the cardiomarker. 15:00 – How will Syn2bio finance its research and projects? 18:30 – Commercialization plan for the cardiomarker. 23:00 – Market potential for the cardiomarker. 27:30 – Syn2bio valuation and the prospect of value release after the spin-off. 32:00 – Prospects for the approval of HistoSonic. 35:00 – Prospects for further robotization in surgery and medicine. 41:00 – Competition from Chinese surgical robots. 46:00 – Synektik's split schedule and future.